Education
About Us
Working with TipRanks
Follow Us
Tandem Diabetes Care (TNDM)
NASDAQ:TNDM
TNDM Stock Chart & Stats
$18.94
-$0.45(-1.21%)
At close: 4:00 PM EST
$18.94
-$0.45(-1.21%)
Day’s Range― - ―
52-Week Range$9.98 - $37.35
Previous CloseN/A
Volume336.73K
Average Volume (3M)1.12M
Market Cap
$1.29B
Enterprise Value$1.64B
Total Cash (Recent Filing)$319.11M
Total Debt (Recent Filing)$449.28M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Feb 19, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding67,802,360
10 Day Avg. Volume1,330,804
30 Day Avg. Volume1,121,224
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)8.96
Price to Sales (P/S)2.51
P/FCF Ratio472.08
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue1.63
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda-9.13
Forecast
1Y Price Target
$26.81Price Target Upside41.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
International ExpansionMarket penetration outside the United States for pump and patch insulin delivery remains early, implying significant international revenue upside as direct sales and renewals scale.
Pricing And Margin ImprovementRevenue beats driven by U.S. pharmacy pricing and favorable currency effects, together with expanding gross margins, indicate pricing and channel shifts can materially improve cash flow and profitability.
Profitability And New Product CycleAnalyst expects improving profitability and a growth-accelerating new product cycle that should strengthen the company's financial profile.
Bears Say
Elevated ExpectationsAnalysts believe initial expectations for company performance are likely too high and may already be reflected in the share price, increasing the risk of disappointment if execution slips.
U.S. New Starts And CompetitionManagement indicates U.S. new patient starts declined for multiple years and expects a return to growth only in 2026, suggesting near-term pressure on revenue and market share from intense competitive dynamics.
Valuation And Retracement RiskThe stock's strong rebound has lifted valuation, which could lead to a sharp retracement if upcoming guidance or operating results fail to justify current levels.
Tandem Diabetes Care News
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $9.98 and its highest was $37.35 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $1.29B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Feb 19, 2026 which is in 13 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Nov 06, 2025. The company reported -$0.313 earnings per share for the quarter, beating the consensus estimate of -$0.329 by $0.016.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.09.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 67,802,360 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.313 in its last earnings report, beating expectations of -$0.329. Following the earnings report the stock price went up 21.98%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in TNDM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.81 (41.55% Upside)
$26.81 (41.55% Upside)
Blogger Sentiment
Bullish
TNDM Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 682.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.37%
12-Months-Change
Fundamentals
Return on Equity
-109.73%
Trailing 12-Months
Asset Growth
-8.67%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
TNDM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Tandem Diabetes Care's earnings call for the third quarter of 2025 reflected significant achievements, including record sales and margin improvements, driven by strategic initiatives in pricing, product innovation, and pharmacy expansion. However, challenges remain in the form of competitive pressures on new pump starts and transition-related impacts in Europe. Overall, the highlights significantly outweigh the lowlights, suggesting a strong positive outlook.View all TNDM earnings summariesTNDM Revenue Breakdown
74.21% U.S.
25.79% International
TNDM Stock 12 Month Forecast
Average Price Target
$26.81
▲(41.55% Upside)
Technical Analysis
Ownership Overview
0.77% Insiders
24.24% Mutual Funds
1.88% Other Institutional Investors
48.40% Public Companies and Individual Investors